Houston Methodist

Engineering Prodrug Therapies For Infectious Disease and Cancer Applications

We have developed a new prodrug therapeutic platform for cell, protein, and small molecule combination therapies termed “drugamers”. This platform has been initially developed against pulmonary infections, where they have shown excellent activity in highly lethal disease models. The platform has been further broadened to include other infectious disease targets such as malaria, HIV and SARS-CoV-2, as well as for oncology drug therapy with kinase inhibitors and chemotherapeutic drugs. Recent advances across these applications will be covered.

Dial-In Information

This virtual event will be stream online via/WebEX.

WebEX Link: https://houstonmethodist.webex.com/houstonmethodist/j.php?MTID=m098ec9b213ba1bb92108cb4742e72392

Friday, October 22 at 1:00pm to 2:00pm

Virtual Event
Event Type


Attendance Options

Livestream Video


Clinical, Research


http:// https://houstonmethodist.webe...

Department & Center
Academic Institute, Department of Nanomedicine

Patrick Stayton, Department of Bioengineering & Molecular Engineering & Sciences Institute, University of Washington

Contact Email


Google Calendar iCal Outlook